Curated News
By: NewsRamp Editorial Staff
September 11, 2026
TransCode Therapeutics Retires CFO, Names Interim Successor
TLDR
- TransCode Therapeutics appoints interim CFO John Tattory, bringing extensive life science financial expertise to strengthen leadership during its cancer therapy development.
- TransCode Therapeutics CFO Tom Fitzgerald retired immediately, and John Tattory, with over 25 years in pharma and biotech finance, became interim CFO.
- TransCode Therapeutics advances RNA immuno-oncology therapies for high-risk cancers, aiming to improve outcomes and offer hope to patients with limited options.
- TransCode Therapeutics named John Tattory interim CFO after Tom Fitzgerald's retirement, adding a leader with experience at Bristol-Myers Squibb and Ernst & Young.
Impact - Why it Matters
This leadership transition comes at a critical time for TransCode Therapeutics as it advances its pipeline of RNA-based cancer therapies. The appointment of an interim CFO with extensive life science financial expertise could provide stability and strategic guidance. Investors should monitor how this change affects the company's financial strategy and clinical development timelines. The news also highlights the ongoing challenges and opportunities in the immuno-oncology space, where TransCode aims to make a significant impact with its innovative treatments.
Summary
TransCode Therapeutics (NASDAQ: RNAZ), a clinical stage immuno-oncology and RNA company focused on high-risk and advanced cancers, has announced a leadership change. Chief Financial Officer Tom Fitzgerald, who has served since July 2018, is retiring effective immediately and will step down from the board of directors, though he will continue to provide transition services. The company has appointed John Tattory as interim CFO, effective immediately. Tattory brings over 25 years of financial and operational leadership experience in the pharmaceutical, medical device, and biotechnology sectors. His background includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he is a managing director at Stout Risius Ross, providing consulting CFO services to privately held life science companies.
TransCode Therapeutics is developing innovative treatments for metastatic cancers. Its lead candidate, TTX-MC138, targets tumors that overexpress microRNA-10b, a biomarker of metastasis. The company also has a portfolio of first-in-class candidates designed to activate the immune system against cancer cells. Investors can find more information in the company’s newsroom at https://nnw.fm/RNAZ. The full press release is available at https://nnw.fm/8G3ik.
The announcement was distributed via NetworkNewsWire (“NNW”), a specialized communications platform for financial news and content distribution. NNW is part of the Dynamic Brand Portfolio @ IBN, which offers wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit https://www.NetworkNewsWire.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Therapeutics Retires CFO, Names Interim Successor
